Literature DB >> 18792920

PGD on a recombinant allele: crossover between the TSC2 gene and 'linked' markers impairs accurate diagnosis.

Gheona Altarescu1, Talia Eldar Geva, Barry Brooks, Ehud Margalioth, Ephrat Levy-Lahad, Paul Renbaum.   

Abstract

OBJECTIVE: Accounting for possible recombinations in developing an accurate preimplantation genetic diagnosis (PGD) protocol based on familial haplotypes.
METHODS: Haplotypes were constructed from genomic DNA in a family where the male was affected with tuberous sclerosis complex (TSC). Embryos were biopsied at day 3, and single blastomeres were analyzed by multiplex polymerase chain reactions (PCRs) including multiple microsatellite markers and single-cell sequencing.
RESULTS: Informative markers used in the initial haplotype analysis, based on the genomic DNA of the parents and affected child, were analyzed in the first PGD cycle. All embryos appeared to show recombination and none were transferred. Prior to the next cycle, the parents of the affected male were included in the haplotype analysis, demonstrating that the affected child had a recombinant allele. In the second PGD cycle, two non-recombinant intragenic single nucleotide polymorphisms (SNPs) were used with the TSC2 mutation and four microsatellite markers for a second PGD cycle. In this cycle two wild-type embryos were transferred, resulting in the birth of a healthy girl carrying the wild-type TSC2 allele.
CONCLUSIONS: PGD analysis requires the use of more than one meiosis for constructing accurate haplotypes. Testing for multiple closely linked markers and the familial mutation are necessary to detect recombination events and enable precise diagnosis. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18792920     DOI: 10.1002/pd.2070

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

1.  The clinical application of preimplantation genetic diagnosis for the patient affected by congenital contractural arachnodactyly and spinal and bulbar muscular atrophy.

Authors:  Linjun Chen; Zhenyu Diao; Zhipeng Xu; Jianjun Zhou; Wanjun Wang; Jie Li; Guijun Yan; Haixiang Sun
Journal:  J Assist Reprod Genet       Date:  2016-07-09       Impact factor: 3.412

2.  Familial haplotyping and embryo analysis for Preimplantation genetic diagnosis (PGD) using DNA microarrays: a proof of principle study.

Authors:  G Altarescu; D A Zeevi; S Zeligson; S Perlberg; T Eldar-Geva; E J Margalioth; E Levy-Lahad; P Renbaum
Journal:  J Assist Reprod Genet       Date:  2013-07-06       Impact factor: 3.412

3.  Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations.

Authors:  David A Zeevi; Gheona Altarescu; Ariella Weinberg-Shukron; Fouad Zahdeh; Tama Dinur; Gaya Chicco; Yair Herskovitz; Paul Renbaum; Deborah Elstein; Ephrat Levy-Lahad; Arndt Rolfs; Ari Zimran
Journal:  J Clin Invest       Date:  2015-08-31       Impact factor: 14.808

4.  Severe combined immunodeficiency (SCID): from the detection of a new mutation to preimplantation genetic diagnosis.

Authors:  Reut Tomashov-Matar; Galia Biran; Irina Lagovsky; Neomi Kotler; Anat Stein; Benjamin Fisch; Onit Sapir; Mordechai Shohat
Journal:  J Assist Reprod Genet       Date:  2012-04-22       Impact factor: 3.412

5.  Birth of a healthy infant following preimplantation PKHD1 haplotyping for autosomal recessive polycystic kidney disease using multiple displacement amplification.

Authors:  Eduardo C Lau; Marleen M Janson; Mark R Roesler; Ellis D Avner; Estil Y Strawn; David P Bick
Journal:  J Assist Reprod Genet       Date:  2010-05-20       Impact factor: 3.412

6.  Preimplantation Genetic Testing for Monogenic Kidney Disease.

Authors:  Rozemarijn Snoek; Marijn F Stokman; Klaske D Lichtenbelt; Theodora C van Tilborg; Cindy E Simcox; Aimée D C Paulussen; Jos C M F Dreesen; Franka van Reekum; A Titia Lely; Nine V A M Knoers; Christine E M de Die-Smulders; Albertien M van Eerde
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-27       Impact factor: 8.237

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.